The proposed studies are aimed at understanding how the HIV-1 Gag polyprotein and its constituent matrix (MA) and capsid (CA] domains function during viral replication. During the current funding period we identified the structural determinants responsible for targeting HIV-1 Gag to virus assembly sites on the plasma membrane (PM). Speciflcally, we showed that phosphatidyIinositoI-4,5-bisphosphate (PIP2), a constituent ofthe PM, binds to a conserved cleft on the HIV-1 MA protein and triggers exposure ofthe N-terminal myristyl group. The unsaturated 2'-acyl chain of PIP2 is sequestered within the cleft ofthe protein, and exposure ofthe saturated 1'- chain and myristyl group explains how HIV-1 Gag is targeted specifically to lipid raft assembly sites. We further showed that conservative mutations that mistarget Gag to the cytoplasm in vivo "turn off the HIV-1 myristyl switch;that HlV-2 Gag trafficking is also P1P2 dependent;and that the switch behavior of HIV-2 MA is more tightly regulated than that of HIV-1, which could explain the poor replication properties ofthe virus in some cell types and in humans. In addition, we determined the first atomic level strucuture of an antiviral assembly inhibitor bound to the HIV-1 CA protein. We are now poised to extend studies to macromolecular interacdons that occur during HIV assembly, including interactions among viral constituents and between viral and cellular constituents. A new system for detecting interactions between HIV-1 MA and the intra-viral segment ofthe envelope glycoprotein GP41 has been developed, which will be used to identify specific interactions and structures responsible for recuriting the envelope protein into assembling particles. Studies ofthe myristyl switch will be extended to animal viruses commonly used as models for HIV-1 and for drug testing, Including SIV and BLV. New efforts will be made to identify compounds that bind to conserved sites on HlV-1, HIV-2, and SIV MA and inhibit myristate exposure. Finally, based on our high resolution structure ofthe CA:CAP-1 complex, and as part ofa new collaboration with Vironova Pharmaceuticals (Sweden), we intend to rationally design capsid assembly inhibitors with improved antiviral properties.

Public Health Relevance

(See inslmctions): As HIV continues to evolve, it is increasingly important to develop new therapies that exploit different viral targets. The proposed studies aim to enhance understanding ofthe molecular structures and mechanisms associated with HIV-1 assembly and maturation and to facilitate the rational design of new therapeutics that inhibit this phase of replication.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Method to Extend Research in Time (MERIT) Award (R37)
Project #
Application #
Study Section
Special Emphasis Panel (NSS)
Program Officer
Sharma, Opendra K
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Maryland Balt CO Campus
Schools of Arts and Sciences
United States
Zip Code
Checkley, Mary Ann; Luttge, Benjamin G; Mercredi, Peter Y et al. (2013) Reevaluation of the requirement for TIP47 in human immunodeficiency virus type 1 envelope glycoprotein incorporation. J Virol 87:3561-70
Lu, Kun; Heng, Xiao; Summers, Michael F (2011) Structural determinants and mechanism of HIV-1 genome packaging. J Mol Biol 410:609-33
Hamard-Peron, E; Juillard, F; Saad, J S et al. (2010) Targeting of murine leukemia virus gag to the plasma membrane is mediated by PI(4,5)P2/PS and a polybasic region in the matrix. J Virol 84:503-15
Valentine, Kathleen G; Peterson, Ronald W; Saad, Jamil S et al. (2010) Reverse micelle encapsulation of membrane-anchored proteins for solution NMR studies. Structure 18:9-16
Saad, Jamil S; Ablan, Sherimay D; Ghanam, Ruba H et al. (2008) Structure of the myristylated human immunodeficiency virus type 2 matrix protein and the role of phosphatidylinositol-(4,5)-bisphosphate in membrane targeting. J Mol Biol 382:434-47
Kyere, Sampson K; Joseph, Prem Raj B; Summers, Michael F (2008) The p12 domain is unstructured in a murine leukemia virus p12-CA(N) Gag construct. PLoS One 3:e1902
Kelly, Brian N; Kyere, Sampson; Kinde, Isaac et al. (2007) Structure of the antiviral assembly inhibitor CAP-1 complex with the HIV-1 CA protein. J Mol Biol 373:355-66
Saad, Jamil S; Loeliger, Erin; Luncsford, Paz et al. (2007) Point mutations in the HIV-1 matrix protein turn off the myristyl switch. J Mol Biol 366:574-85
Saad, Jamil S; Kim, Andrew; Ghanam, Ruba H et al. (2007) Mutations that mimic phosphorylation of the HIV-1 matrix protein do not perturb the myristyl switch. Protein Sci 16:1793-7
Saad, Jamil S; Miller, Jaime; Tai, Janet et al. (2006) Structural basis for targeting HIV-1 Gag proteins to the plasma membrane for virus assembly. Proc Natl Acad Sci U S A 103:11364-9

Showing the most recent 10 out of 30 publications